CRDF stock news · Cardiff Oncology, Inc.
Get alerts for CRDF
Follow Cardiff Oncology, Inc. (CRDF) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CRDFFree on the App Store and Google Play, or on the web.
Cardiff Oncology got FDA Fast Track approval for its drug onvansertib to treat a type of colon cancer.
Good for CRDFCardiff Oncology received FDA Fast Track designation for onvansertib; its trial showed a 72.2% response rate versus 42.1% with the comparison treatment. This is positive, though approval remains ahead.